Sevion Therapeutics (SVON) versus Anavex Life Sciences (AVXL) Head to Head Review

Sevion Therapeutics (OTCMKTS: SVON) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Institutional & Insider Ownership

22.7% of Anavex Life Sciences shares are held by institutional investors. 7.7% of Sevion Therapeutics shares are held by company insiders. Comparatively, 11.6% of Anavex Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Sevion Therapeutics and Anavex Life Sciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sevion Therapeutics N/A -264.80% -81.73%
Anavex Life Sciences N/A -69.24% -62.66%

Volatility & Risk

Sevion Therapeutics has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500. Comparatively, Anavex Life Sciences has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500.

Earnings and Valuation

This table compares Sevion Therapeutics and Anavex Life Sciences’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sevion Therapeutics $80,000.00 209.85 -$5.79 million ($4.91) -0.06
Anavex Life Sciences N/A N/A -$13.46 million ($0.34) -7.32

Sevion Therapeutics has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Sevion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Sevion Therapeutics and Anavex Life Sciences, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sevion Therapeutics 0 0 0 0 N/A
Anavex Life Sciences 0 0 2 0 3.00

Anavex Life Sciences has a consensus target price of $10.00, indicating a potential upside of 301.61%. Given Anavex Life Sciences’ higher probable upside, analysts plainly believe Anavex Life Sciences is more favorable than Sevion Therapeutics.

Summary

Anavex Life Sciences beats Sevion Therapeutics on 7 of the 11 factors compared between the two stocks.

About Sevion Therapeutics

Eloxx Pharmaceuticals, Inc., formerly Sevion Therapeutics, Inc., is a development-stage biotech company. The Company is engaged in building and developing a portfolio of therapeutics, from both internal discovery and acquisition, for the treatment of cancer and immunological diseases. The Company is engaged in the development and licensing of technology to discover and engineer monoclonal antibodies. The Company’s product candidates are derived from multiple technology platforms, such as cell-based arrayed antibody discovery, ultralong antibody scaffolds and Chimerasome nanocages. The Company has various antibodies in its preclinical pipeline. The Company’s antibody therapeutic candidates target the potassium channel, voltage dependent (Kv1.3) ion channel, which is essential in the pathogenesis of several autoimmune and inflammatory disorders. Other antibodies in its pipeline target cell surface molecules involved in cancer progression.

About Anavex Life Sciences

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases. The Company’s SIGMACEPTOR Discovery Platform produced small molecule drug candidates with unique modes of action. Sigma receptors may be targets for therapeutics to combat many human diseases, including Alzheimer’s disease. When bound by the appropriate ligands, sigma receptors influence the functioning of multiple biochemical signals that are involved in the pathogenesis (origin or development) of disease.

Receive News & Ratings for Sevion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sevion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply